Testing a new medicine for Cold Agglutinin Disease
Part of Blood & lymphatic clinical trials.
This Phase 1 study checks whether an investigational medicine is safe and tolerable, and how the body processes it. For people with Cold Agglutinin Disease, it also looks at early blood markers of whether the disease responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 18–65 if you’re in the healthy-subject groups (otherwise at least 18).
- You must be non-pregnant and not breastfeeding; you must agree to use contraception if you could become pregnant.
- You must meet the study body size limits (BMI 18–32 and weight >50 kg for the healthy groups).
- You must have had a meningococcal ACWY vaccine within the past 5 years (or at least 14 days before starting).
- If you have Cold Agglutinin Disease (CAD), you must have a confirmed diagnosis, and certain blood tests must fit the study ranges.
- You must be able to understand the study and sign informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine to see how the body handles it and whether it is safe. It is for healthy people, not for treating a disease, and helps researchers decide if the drug can move to the next stage of testing.
This trial tests a single dose of an investigational drug called AMG 691 in healthy Chinese and Japanese volunteers to see how it is processed by the body and how safe it is. This is an early-phase study, so it may help make future treatments safer for people of similar backgrounds.
This trial is testing a new drug called QLS7305, given as a shot under the skin, to see if it is safe in healthy adults. It may help in the future to treat certain conditions.
This study tests a new medicine (INCA033989) given as a shot or IV in healthy adults to see how the body processes it and if it's safe.
This trial tests an investigational drug in healthy people to see how safe it is and how the body processes it. It may help researchers decide if the drug should be studied further for a specific condition.
This Phase 1 trial tests how safe APG-5918 is, how the body processes it, and looks for early signs it may help people with certain types of anemia. It may include healthy volunteers and people with anemia, but the study is very selective to protect participants.
Hear when a new First in Man Study to Evaluate Initial Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.